Traws Pharma, Inc.
TRAW
$2.63
-$0.05-1.87%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,184.51% | 0.44% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,184.51% | 0.44% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1,184.51% | 0.44% | 0.00% | 0.00% | 0.00% |
| SG&A Expenses | 12.85% | 13.06% | 35.13% | 20.72% | 19.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.00% | 28.21% | 22.47% | 11.58% | -6.60% |
| Operating Income | 1.85% | -28.53% | -22.72% | -11.70% | 6.67% |
| Income Before Tax | 87.00% | -671.37% | -778.84% | -597.51% | -557.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 87.00% | -671.37% | -778.84% | -597.51% | -557.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 87.00% | -671.37% | -778.84% | -597.51% | -557.53% |
| EBIT | 1.85% | -28.53% | -22.72% | -11.70% | 6.67% |
| EBITDA | 1.79% | -28.60% | -22.76% | -11.72% | 6.69% |
| EPS Basic | 141.61% | 98.25% | 14.53% | -111.37% | -91.73% |
| Normalized Basic EPS | 29.55% | 2.54% | -33.18% | -5.20% | 10.98% |
| EPS Diluted | 141.44% | 98.02% | 14.52% | -110.74% | -91.17% |
| Normalized Diluted EPS | 29.07% | 2.04% | -33.18% | -5.20% | 10.98% |
| Average Basic Shares Outstanding | 376.07% | 257.55% | 75.54% | 8.98% | 5.48% |
| Average Diluted Shares Outstanding | 383.12% | 264.97% | 75.54% | 8.98% | 5.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |